Physician profile
David Bryan Duff
NPI 1003435801
$2,838.09
in general payments reported to CMS, 2019-2025
21 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,280 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.58 |
| Education | $190.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $389.45 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $344.29 | 2024-2025 | |
| Abbvie INC. | $277.20 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $274.58 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $226.95 | 2024-2025 | |
| Amgen INC. | $209.28 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $179.97 | 2024-2025 | |
| Incyte Corporation | $147.99 | 2024-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $146.78 | 2024 | Tremfya |
| Janssen Biotech, INC. | $136.69 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $109.03 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $73.42 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Lilly USA, LLC | $69.47 | 2024-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $57.53 | 2024-2025 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $34.90 | 2024-2025 | Bimzelx |
| Almirall LLC | $29.77 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.17 | 2025 | Spevigo |
| Leo Pharma INC. | $18.14 | 2025 | Adbry |
| Strata Skin Sciences, INC. | $13.15 | 2024 | Xtrac |
| Organon LLC | $8.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.